Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...
Lucerne (ots) - World Cancer Day every 4th of February is a global uniting movement led by the Union for International Cancer Control (UICC). MSD (Merck Sharp & Dohme) is a proud sponsor of this initiative, joining the conversation to create a groundswell of awareness and action that will enable powerful ...
Lucerne (ots) - - Company will open a new location in Zurich, focused on accelerating research, data and commercialization of our medicines and vaccines - Lucerne will remain the center of MSD's presence in Switzerland MSD (Merck Sharp & Dohme AG) today announced that it will establish a new office in Zurich, Switzerland, aimed at accelerating the ...
Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...
Zurich (ots) - - Indication: Health Tips from EAACI can be downloaded free of charge as a pdf-file under: http://www.presseportal.ch/de/pm/100018272/?langid=2 - EAACI, the largest European organisation in the field of allergy, immunology and asthma, today hosted a specialist forum on "Swine-flu - a threat for asthmatics? What people ...